Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Mária u. 41, H-1085, Budapest, Hungary.
Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary.
Br J Dermatol. 2019 Apr;180(4):802-809. doi: 10.1111/bjd.16883. Epub 2018 Sep 19.
No studies to date have employed the EuroQoL EQ-5D questionnaire to assess health-related quality of life (HRQoL) in patients with pemphigus.
To evaluate the HRQoL of patients with pemphigus by the EQ-5D and to analyse the convergent and known-groups validity of the EQ-5D in this patient population.
Between 2014 and 2017, a multicentre cross-sectional study was carried out. Outcome measures included the five-level EQ-5D (EQ-5D-5L), Dermatology Life Quality Index (DLQI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and an average pain intensity visual analogue scale (VAS) for the past 3 months.
In total, 109 consecutive patients with pemphigus participated in the study (mean age 57 years; 64% women). Among the EQ-5D dimensions, the most problems were reported regarding pain/discomfort (50%), mobility (43%) and anxiety/depression (43%). No significant difference was found in mean EQ-5D index scores between patients with pemphigus vulgaris and those with pemphigus foliaceus (0·81 vs. 0·86, P = 0·14). The mean EQ-5D index scores of patients with limited, moderate, significant and extreme pemphigus were 0·88, 0·82, 0·72 and 0·67, respectively (P = 0·001). The number of comorbidities was associated with greater impairment in EQ-5D index scores (P < 0·001). DLQI (r = -0·62, P < 0·001) and the average pain intensity VAS (r = -0·59, P < 0·001) more strongly correlated with the EQ-5D index scores than did ABSIS (r = -0·40, P < 0·001).
This is the first study employing the EQ-5D questionnaire in pemphigus. The EQ-5D is a valid measure of HRQoL in patients with pemphigus that can be useful both in clinical practice and in economic evaluations to assess the health gains associated with new effective treatments.
目前尚无研究采用欧洲五维健康量表（EQ-5D）评估天疱疮患者的健康相关生活质量（HRQoL）。
采用 EQ-5D 评估天疱疮患者的 HRQoL，并分析该患者人群中 EQ-5D 的收敛和已知组有效性。
2014 年至 2017 年间进行了一项多中心横断面研究。结局指标包括 5 级 EQ-5D（EQ-5D-5L）、皮肤病生活质量指数（DLQI）、自身免疫性大疱性皮肤病严重程度评分（ABSIS）和过去 3 个月的平均疼痛强度视觉模拟量表（VAS）。
共有 109 例连续天疱疮患者参与了该研究（平均年龄 57 岁，64%为女性）。在 EQ-5D 维度中，报告最多的问题是疼痛/不适（50%）、行动不便（43%）和焦虑/抑郁（43%）。寻常型天疱疮和落叶型天疱疮患者的平均 EQ-5D 指数评分无显著差异（0.81 比 0.86，P=0.14）。局限性、中度、显著和极重度天疱疮患者的平均 EQ-5D 指数评分分别为 0.88、0.82、0.72 和 0.67（P=0.001）。共病数量与 EQ-5D 指数评分的损害程度呈正相关（P＜0.001）。DLQI（r=-0.62，P＜0.001）和平均疼痛强度 VAS（r=-0.59，P＜0.001）与 EQ-5D 指数评分的相关性强于 ABSIS（r=-0.40，P＜0.001）。
这是首次在天疱疮中使用 EQ-5D 问卷的研究。EQ-5D 是评估天疱疮患者 HRQoL 的有效方法，在临床实践和经济评估中均有用，可评估新有效治疗方法带来的健康获益。
